Daiichi Sankyo Company, Limited aims to ring up sales of more than JPY 150 billion ($1.7 billion) in emerging markets in fiscal 2012, up 70% over forecasts for the 2010. Group sales are projected to climb 19% to JPY 1.15 trillion in fiscal 2012.

Daiichi Sankyo Company, Limited appointed Ryuzo Takada as Member of the board, Hitoshi Matsuda as member of the board, senior executive officer and head of administration dividion of japan company, Tsutomu Une as member of the board, senior executive officer and Global Corporate Strategy Officer, Hybrid Business, Intellectual Property, Takeshi Ogita as member of the board, senior executive officer and Global Corporate Strategy Officer HR, IT, business development, Global marketing, Joji Nakayama as Executive vice president, president of Japan company, Kazunori Hirokawa as Senior executive officer, Head of R&D division, Akira Nagano as Senior executive officer, head of quality and safety management division, and head of business intelligence division of Japan company, Yoshikazu Takano as Senior Executive Officer, Head of group CSR and in charge of external affairs, Kazuhiko Tanzawa as Executive Officer, External Innovation, Kyohei Nonose as Executive Officer, Head of Group HR Strategy, Manabu Sakai as executive Officer, Global corporate finance officer, Ryouichi Kibushi as Executive Officer Head of Sales & Marketing Division of Japan company, Shuhi Handa as Corporate Officer, President of ASCA Company, Hideyuki Haruyama as corporate Officer, In charge of Research of R&D division, Katsuaki Miyoshi as Corporate Officer, General Manager of Tokyo Branch, Sales & Marketing Division of Japan Company, Satoshi Kunitada as Corporate Officer, In charge of Japan Development of R&D division, Shinichi Terano as Corporate Officer, General manager of product marketing department, sales & marketing division of Japan company, Toshiaki Sai as Corporate Officer, General manager of corporate communications department, Yoshihiko Suzuki as Corporate Adviser (board member at Sankyo Foundation of Life Science), Shinsei Tamai as Representative Director and President of Daiichi Sankyo Espha co. Ltd.

Daiichi Sankyo Company, Limited and Ranbaxy Laboratories Ltd. announced that Daiichi Sankyo will establish Daiichi Sankyo Espha Co. Ltd. on April 1st, 2010. Daiichi Sankyo Espha will market generic drugs, as well as Daiichi Sankyos products which have gained a well-established reputation in the market. Completing their strategic alliance in November 2008 to form the unique Hybrid Business Model, Daiichi Sankyo and Ranbaxy (collectively the Group) have been moving forward to fully leverage the Model. The expanded global reach enables leading market positions in both developed and emerging markets through the supply of innovative and established pharmaceuticals.

Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs

Daiichi Sankyo to sell generics in Japan: report

Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs

Q3 2010 DAIICHI SANKYO CO LTD Earnings Release - 10:00 pm ET

Asia Markets: Japanese companies offer easy exposure to India

Q2 2010 DAIICHI SANKYO CO LTD Earnings Release - 11:30 pm ET

Depressing Data Cannot Suppress Tokyo Shares

Lilly's Prasugrel One Step Closer To Market